Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

NCT04198922 ↗

Phase 2 Active not recruiting 51 enrolled Fred Hutchinson Cancer Center AstraZeneca · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Timeline

Start: 2020-12-11
Primary completion: 2025-09-29
Completion: 2027-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acalabrutinib	Small molecule	100 mg	Oral

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Summary

Timeline

Drugs

Indications